相关实验视频

Updated: Jul 21, 2025

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

作为复发性子宫内膜癌的初始系统性治疗的美德:单一的机构研究

Maiko Korosue¹, Kohei Nakagawa¹, Kanako Yoshiyasu²

¹Department of Obstetrics and Gynecology, School of Medicine, Hyogo Medical University, Hyogo, Japan.

Anticancer research

|July 27, 2023

概括

激素治疗用美德乙酸 (MPA) 显示在复发的G1/G2子宫内膜癌 (EC) 中具有有效性,特别是在ER/PR阳性病例中. 治疗通常耐受良好,有轻微的毒性,使其成为可行的初始系统性治疗选择.

科学领域:

妇科瘤学妇科瘤学
内分泌学在内分泌学.
医学瘤学医学瘤学

背景情况:

激素治疗是先进或复发的G1/G2子宫内膜癌 (EC) 的首选初始全身治疗方法,因为它具有有效性,安全性和成本效益.
有限的报道存在于高剂量的美德乙酸 (MPA) 对于EC,需要进一步调查.

研究的目的:

评估高剂量MPA的疗效和安全性,作为G1或G2子宫内膜癌复发患者的初始全身疗法.
评估与MPA治疗相关的长期结果,包括无进展生存 (PFS) 和毒性,在这个患者群体中.

主要方法:

一项回顾性研究审查了16名在2010年1月至2022年12月期间接受高剂量MPA治疗的G1/G2 EC复发患者.
分析了接受MPA (200毫克/天) 的患者;一些人也接受了阿司匹林 (100毫克/天). 排除标准包括保护生育能力的治疗或先前的化疗.
评估的结果包括应答率,PFS和不良事件.

主要成果:

患者的中位数年龄为65岁,中位数BMI为22.6kg/m2,ECOG性能状态为0.
整体应答率为44%,PFS的中位数为6.9个月. 两年的PFS在阳性雌激素受体 (ER) 和孕激素受体 (PR) 组织的患者中为35%.
副作用通常是轻微的;由于副作用,两名患者停止了MPA治疗,一名患者经历了2级深静脉血栓形成.

结论:

高剂量的甲 (MPA) 是ER和PR阳性子宫内膜癌的有效长期治疗方法.
由于其可管理的毒性特征,可以将MPA激素治疗推为符合条件的EC患者的初始全身疗法.

关键词:

麦德洛克西孕的使用方法这是子宫内膜癌的癌症.荷尔蒙治疗荷尔蒙治疗

更多相关视频

Author Spotlight: A Reproductive Hysteroscopy Approach for Complete Endometrial Polyp Removal and Enhanced Endometrial Receptivity

Author Spotlight: A Reproductive Hysteroscopy Approach for Complete Endometrial Polyp Removal and Enhanced Endometrial Receptivity

Published on: August 2, 2024

Two Methods for Establishing Primary Human Endometrial Stromal Cells from Hysterectomy Specimens

Two Methods for Establishing Primary Human Endometrial Stromal Cells from Hysterectomy Specimens

Published on: May 23, 2014

相关概念视频

Ovarian Cycle

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Hormonal Regulation of the Menstrual Cycle

Hormonal Regulation of the Menstrual Cycle

The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...